ACCELERATING LIFE SCIENCE INNOVATION
Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.
ACCELERATING LIFE SCIENCE INNOVATION
Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.
ACCELERATING LIFE SCIENCE INNOVATION
Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.
“Challenges which others have deemed unsolvable are the problems we are solving.”
~ Jeffrey S. Aronin
Paragon founder, chairman and CEO
Portfolio
Since 2017, Paragon has successfully launched seven portfolio companies, including a recent upsized IPO, while maintaining a consistent flow of companies in development.
Leveraging its proprietary fibroblast technology platform to expand an innovative gene therapy pipeline, developing personalized treatments for underserved disorders, including epidermolysis bullosa and localized scleroderma.
Concentrating on cell therapy treatments for serious diseases with high, unmet needs with an initial focus on the eye, including geographic atrophy age-related macular degeneration and advanced retinitis pigmentosa.
Creating treatments for central nervous system movement disorders and fluency disorders, including Tourette syndrome and childhood-onset fluency disorder (stuttering) in adults.
Evozyne is combining the exquisite complexity of nature with advanced machine learning to create novel proteins with extraordinary impact across a variety of industries.
Commercializing biopharmaceutical treatment options for people living with rare diseases, including disorders of sleep and wakefulness, such as narcolepsy, Prader-Willi syndrome and myotonic dystrophy.
Assisting radiologists to significantly improve clinical assessment and characterization of cancerous breast abnormalities through artificial intelligence-driven technology that enhances clinical insights.
Developing first in-kind therapies to treat oral premalignant lesions, a high, unmet need, by eliminating lesions before they become malignant.
News
Paragon’s Portfolio Company Emalex Biosciences Announces Positive Topline Results from Phase 2b Clinical Study Evaluating Ecopipam for Pediatric Tourette Syndrome
Paragon’s Portfolio Company Emalex Biosciences Announces Positive Topline Results from Phase 2b Clinical Study Evaluating Ecopipam for Pediatric Tourette Syndrome Statistically significant, [...]
Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disorder
Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disorder Current enrollment for stuttering study is at [...]
Emalex Biosciences Announces Completion of Patient Enrollment in Phase 2b Clinical Trial Evaluating Ecopipam (EBS-101) for Pediatric Patients with Tourette Syndrome
Paragon Biosciences’ Portfolio Company Focuses on Areas with High Unmet Needs Chicago, June 22, 2021 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical [...]
Paragon’s Portfolio Company Emalex Biosciences Announces Positive Topline Results from Phase 2b Clinical Study Evaluating Ecopipam for Pediatric Tourette Syndrome
Paragon’s Portfolio Company Emalex Biosciences Announces Positive Topline Results from Phase 2b Clinical Study Evaluating Ecopipam for Pediatric Tourette Syndrome Statistically significant, [...]
Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disorder
Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disorder Current enrollment for stuttering study is at [...]
Emalex Biosciences Announces Completion of Patient Enrollment in Phase 2b Clinical Trial Evaluating Ecopipam (EBS-101) for Pediatric Patients with Tourette Syndrome
Paragon Biosciences’ Portfolio Company Focuses on Areas with High Unmet Needs Chicago, June 22, 2021 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical [...]
Paragon’s Portfolio Company Emalex Biosciences Announces Positive Topline Results from Phase 2b Clinical Study Evaluating Ecopipam for Pediatric Tourette Syndrome
Paragon’s Portfolio Company Emalex Biosciences Announces Positive Topline Results from Phase 2b Clinical Study Evaluating Ecopipam for Pediatric Tourette Syndrome Statistically significant, [...]
Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disorder
Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disorder Current enrollment for stuttering study is at [...]
Emalex Biosciences Announces Completion of Patient Enrollment in Phase 2b Clinical Trial Evaluating Ecopipam (EBS-101) for Pediatric Patients with Tourette Syndrome
Paragon Biosciences’ Portfolio Company Focuses on Areas with High Unmet Needs Chicago, June 22, 2021 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical [...]
